Benlysta (belimumab) - GSK
Lupkynis (voclosporin) - Aurinia Pharma, Otsuka
Rituxan (rituximab) - Biogen, Zenyaku Kogyo, Roche
Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku
cyclophosphamide - Generic mfg.
Clinical Advances in Lupus Nephritis - A New Age in Biologic Therapy (PAS 2023) - Mar 8, 2023 - Pres time: May 1, 2023; 08:00 AM - 09:30 AM; Location: Convention Center: 201; "Topic/title: Do we really need cyclophosphamide?...Topic/title: Voclosporin and calcineurin inhibitors does it really improve outcomes in lupus nephritis?...Topic/title: Utility of Belimumab as a steroid sparing agent in lupus nephritis Objective: Discuss the role of Belimumab in lupus treatment and effect on reducing long term steroid exposure in lupus nephritis...Discuss recent clinical trials on B cell depleting agents such as Obinutuzumab, Rituximab/Obinutuzumab, and the potential for CAR T cell B cell depletion for lupus treatment...Recognize risks of agents used in treatment of lupus nephritis. Describe new therapeutic options for treatment of lupus nephritis." 
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
https://2023.pas-meeting.org/fsPopup.asp?efp=WFJFTkxUVUcxNzk2Mw&PresentationID=1193752&rnd=0.6666063&mode=sessionInfo
 
Jerome Lane, MD; Ellen Cody, MD, MS
 
Mar 8, 2023
 
Prev Next